Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) Equity Average (2016 - 2025)

Historic Equity Average for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $3.5 million.

  • BioRestorative Therapies' Equity Average fell 6608.0% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 6608.0%. This contributed to the annual value of $9.3 million for FY2024, which is 866.7% down from last year.
  • BioRestorative Therapies' Equity Average amounted to $3.5 million in Q3 2025, which was down 6608.0% from $5.5 million recorded in Q2 2025.
  • BioRestorative Therapies' 5-year Equity Average high stood at $13.8 million for Q1 2022, and its period low was -$4.3 million during Q3 2021.
  • For the 5-year period, BioRestorative Therapies' Equity Average averaged around $7.0 million, with its median value being $8.4 million (2023).
  • Per our database at Business Quant, BioRestorative Therapies' Equity Average skyrocketed by 78427.96% in 2022 and then crashed by 6608.0% in 2025.
  • BioRestorative Therapies' Equity Average (Quarter) stood at $8.4 million in 2021, then grew by 20.08% to $10.0 million in 2022, then grew by 3.44% to $10.4 million in 2023, then decreased by 10.8% to $9.3 million in 2024, then crashed by 61.93% to $3.5 million in 2025.
  • Its Equity Average stands at $3.5 million for Q3 2025, versus $5.5 million for Q2 2025 and $7.3 million for Q1 2025.